12413 results
-
List item
Human medicine European public assessment report (EPAR): Atazanavir Mylan
atazanavir (as sulfate), HIV Infections
Date of authorisation: 22/08/2016,
, Revision: 9, Authorised, Last updated: 08/12/2020
Atazanavir Mylan HIV Infections … Atazanavir Mylan … by injection or infusion (drip), do not need to be tested … -
List item
Human medicine European public assessment report (EPAR): Atazanavir Krka
atazanavir (as sulfate), HIV Infections
Date of authorisation: 25/03/2019,, Authorised, Last updated: 15/05/2019
Atazanavir Krka HIV Infections … Atazanavir Krka … Atazanavir Krka atazanavir atazanavir (as sulfate … -
List item
Human medicine European public assessment report (EPAR): Reyataz
atazanavir (as sulfate), HIV Infections
Date of authorisation: 01/03/2004, Revision: 50, Authorised, Last updated: 15/09/2020atazanavir sulfate … for the public Reyataz atazanavir This document is a summary … contains the active substance atazanavir. It is available as capsules … -
List item
Human medicine European public assessment report (EPAR): Evotaz
cobicistat, atazanavir sulfate, HIV Infections
Date of authorisation: 13/07/2015, Revision: 10, Authorised, Last updated: 29/04/2020atazanavir / cobicistat … for the public Evotaz atazanavir / cobicistat This is a … contains the active substances atazanavir and cobicistat. The medicine … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Evotaz, cobicistat, atazanavir sulfate
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001465-PIP01-13-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral solid dosage form
Decision date: 30/01/2018, Last updated: 18/04/2018, Compliance check: XActive substance cobicistat atazanavir sulfate Therapeutic area … paediatric investigation plan for atazanavir (sulphate) / cobicistat (Evotaz … paediatric investigation plan for atazanavir (sulphate) / cobicistat … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Reyataz, atazanavir sulfate
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000804-PIP01-09-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, Hard oral powder
Decision date: 10/04/2014, Last updated: 27/07/2015, Compliance check: V, 13/02/2015Reyataz Active substance atazanavir sulfate Therapeutic area … paediatric investigation plan for atazanavir (sulphate) (Reyataz), (EMEA-000804-PIP01-09-M02 … paediatric investigation plan for atazanavir (sulphate) (Reyataz), (EMEA-000804-PIP01-09-M02 … -
List item
Referral: Panexcell
Article 31 referrals
Status: European Commission final decision, opinion/position date: 27/02/2020, EC decision date: 24/09/2020, Last updated: 22/10/2020Draft First published: 05/03/2020 … atazanavir atazanavir sulfate Amoxicillin trihydrate iron … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ritonavir, atazanavir sulfate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-002588-PIP01-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 04/12/2019, Last updated: 03/04/2020, Compliance check: XActive substance ritonavir atazanavir sulfate Therapeutic area … ritonavir atazanavir sulfate … -
List item
Referral: Yaz 24+4
ethinylestradiol / drospirenone, associated names: Ethinylestradiol-Drospirenone 24+4, Article 6(12) referrals (prior to January 2010)
Status: European Commission final decision, opinion/position date: 19/04/2012, EC decision date: 03/07/2012, Last updated: 11/01/2013substances, ethinylestradiol and drospirenone, which are derived from natural … derived from oestrogen and drospirenone is derived from progesterone … 24+4 and Ethinylestradiol- Drospirenone 24+4 (ethinylestradiol drospirenone, 0.02 mg/3 mg tablets) Outcome … -
List item
Referral: Yvidually
ethinylestradiol / drospirenone, associated names: Flexyess, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 19/04/2012, EC decision date: 28/09/2012, Last updated: 03/01/2013substances, ethinylestradiol and drospirenone, which are derived from natural … derived from oestrogen and drospirenone is derived from progesterone … names (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets) Outcome … -
List item
Referral: Ethinylestradiol-Drospirenone 24+4
ethinylestradiol / drospirenone, associated names: Yaz 24+4, Article 6(12) referrals (prior to January 2010)
Status: European Commission final decision, opinion/position date: 19/04/2012, EC decision date: 06/07/2012, Last updated: 11/01/201324+4 and Ethinylestradiol- Drospirenone 24+4 (ethinylestradiol drospirenone, 0.02 mg/3 mg tablets) Outcome … substances, ethinylestradiol and drospirenone, which are derived from natural … ethinyl estradiol Drospirenone ethinylestradiol drospirenone … -
List item
Human medicine European public assessment report (EPAR): Multaq (updated)
dronedarone, Atrial Fibrillation
Date of authorisation: 25/11/2009, Revision: 15, Authorised, Last updated: 04/02/2021dronedarone … on the review of Multaq (dronedarone) Outcome of a procedure … contains the active substance dronedarone (400 mg). It was approved … -
List item
Withdrawn application: Draxxin
tulathromycin, date of withdrawal: 11/05/2012, Post-authorisation, Last updated: 04/07/2012Draxxin: Withdrawn application … variation assessment report DRAXXIN 100 mg/ml Solution for injection … marketing authorisation of DRAXXIN for the treatment and prevention … -
List item
Withdrawn application: Draxxin
tulathromycin, date of withdrawal: 17/01/2007, Post-authorisation, Last updated: 17/01/2007Draxxin: Withdrawn application … AUTHORISATION APPLICATION for DRAXXIN International Non-proprietary … Fusobacterium necrophorum. What is Draxxin? Draxxin is an antibiotic. It is a … -
List item
Withdrawn application: Multaq
dronedarone, date of withdrawal: 06/09/2006, Initial authorisation, Last updated: 08/09/2006Non-proprietary Name (INN): dronedarone This product was later … tablets containing 400 mg of dronedarone. What was MULTAQ expected … active substance in MULTAQ, dronedarone, is an anti-arrhythmic agent … -
List item
Human medicine European public assessment report (EPAR): Xigris
drotrecogin alfa (activated), Sepsis, Multiple Organ Failure
Date of authorisation: 22/08/2002,
, Revision: 13, Withdrawn, Last updated: 21/02/2012
drotrecogin alfa (activated … Public statement on Xigris (drotrecogin alfa (activated)) Withdrawal … medicinal product Xigris, drotrecogin alfa (activated), which had … -
List item
Referral: Yasminelle
Drospirenone + Ethinylestradiol, Article 5(11) referrals (prior to January 2010)
Status: European Commission final decision, opinion/position date: 14/12/2007, EC decision date: 17/06/2008, Last updated: 03/07/2008ethinylestradiol and 3 mg of drospirenone. The MAH submitted variation … 2007. The Rapporteur was Dr Jean-Louis Robert and Co-Rapporteur … Robert and Co-Rapporteur was Dr Janos Borvendeg. During their … -
List item
Referral: Belanette
Drospirenone + Ethinylestradiol, Article 5(11) referrals (prior to January 2010)
Status: European Commission final decision, opinion/position date: 14/12/2007, EC decision date: 17/06/2008, Last updated: 03/07/2008ethinylestradiol and 3 mg of drospirenone. The MAH submitted variation … 2007. The Rapporteur was Dr Jean-Louis Robert and Co … Robert and Co- Rapporteur was Dr Janos Borvendeg. During their … -
List item
Orphan designation: Cysteamine hydrochloride for: Treatment of cystinosis
Date of first decision: 15/10/2014, Positive, Last updated: 12/11/2014which is formulated as eye drops, can reduce such deposits … which is formulated as eye drops, can reduce such deposits … Dropcys Dropcys mercaptamine Cysteamine … -
List item
Referral: Combined hormonal contraceptives
desogestrel, gestodene, norgestimate, etonogestrel, drospirenone, dienogest, chlormadinone, nomegestrol, norelgestromin, Article 31 referrals
Status: European Commission final decision, opinion/position date: 16/01/2014, Last updated: 31/01/2014drospirenone, gestodene or desogestrel … Women using a CHC containing drospirenone, gestodene or desogestrel … desogestrel, dienogest, drospirenone, etonogestrel, gestodene … -
List item
Veterinary medicine European public assessment report (EPAR): Draxxin
tulathromycin, Pigs, Cattle, Sheep
Date of authorisation: 11/11/2003, Revision: 23, Authorised, Last updated: 09/06/2020Draxxin … Draxxin … marketing authorisation for DRAXXIN (EMEA/V/C/000077/II/0031 … -
List item
Referral: Zanil and associated names, and generic products thereof
oxyclozanide, associated names: Zanil Suspension, Zanil Fluke Drench, Zanil Fluke Drench 34 mg/ml Oral Suspension, Article 35
Status: European Commission final decision, opinion/position date: 13/07/2017, EC decision date: 28/09/2017, Last updated: 25/10/2017Zanil Suspension Zanil Fluke Drench Zanil Fluke Drench 34 mg/ml Oral Suspension … Intervet Ireland Ltd. Magna Drive Magna Business Park Citywest … 24 Ireland Zanil Fluke Drench Oxyclozanide 34 mg/ml Oral … -
List item
Human medicine European public assessment report (EPAR): Dropcys
mercaptamine, Corneal Diseases, Cystinosis
Date of refusal: 24/06/2016,
, Refused, Last updated: 25/07/2016
Dropcys Corneal Diseases Cystinosis … Dropcys … marketing authorisation for Dropcys (mercaptamine hydrochloride … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dronabinol
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Pain
PIP number: Dronabinol, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 29/10/2010, Last updated: 25/11/2010, Compliance check: XDronabinol Pain … Dronabinol … product specific waiver for dronabinol (EMEA-000643-PIP01-09) in … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Drospirenone
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001495-PIP01-13-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 20/05/2016, Last updated: 27/07/2016, Compliance check: V, 23/03/2018Active substance Drospirenone Therapeutic area Endocrinology … paediatric investigation plan for drospirenone (EMEA- 001495-PIP01-13-M01 … paediatric investigation plan for drospirenone (EMEA- 001495-PIP01-13-M01 …